Alimera Sciences Inc (NASDAQ:ALIM) Expected to Post Quarterly Sales of $12.97 Million

Equities analysts forecast that Alimera Sciences Inc (NASDAQ:ALIM) will announce sales of $12.97 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Alimera Sciences’ earnings, with estimates ranging from $12.94 million to $13.00 million. Alimera Sciences posted sales of $10.92 million during the same quarter last year, which would suggest a positive year over year growth rate of 18.8%. The firm is scheduled to announce its next quarterly earnings report on Monday, July 29th.

On average, analysts expect that Alimera Sciences will report full-year sales of $56.41 million for the current fiscal year, with estimates ranging from $55.89 million to $56.92 million. For the next financial year, analysts anticipate that the business will report sales of $68.88 million, with estimates ranging from $65.50 million to $72.26 million. Zacks’ sales averages are a mean average based on a survey of research analysts that that provide coverage for Alimera Sciences.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings results on Monday, April 29th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. The firm had revenue of $12.89 million for the quarter, compared to analyst estimates of $12.25 million.

A number of research analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of EXACT Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Craig Hallum reiterated a “hold” rating and set a $153.00 price target (up from $128.00) on shares of Cavco Industries in a research note on Tuesday, May 28th. Finally, HC Wainwright reiterated a “buy” rating on shares of Interpace Diagnostics Group in a research note on Friday, June 21st. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $2.50.

Institutional investors and hedge funds have recently modified their holdings of the business. Columbia Pacific Advisors LLC acquired a new position in Alimera Sciences during the first quarter worth about $54,000. B. Riley Wealth Management Inc. grew its position in Alimera Sciences by 23.5% during the fourth quarter. B. Riley Wealth Management Inc. now owns 101,906 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 19,407 shares during the period. Royce & Associates LP grew its position in Alimera Sciences by 60.2% during the fourth quarter. Royce & Associates LP now owns 319,186 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 120,000 shares during the period. Finally, Knott David M grew its position in Alimera Sciences by 3.9% during the first quarter. Knott David M now owns 402,901 shares of the biopharmaceutical company’s stock worth $427,000 after buying an additional 15,000 shares during the period. Institutional investors own 50.73% of the company’s stock.

Shares of Alimera Sciences stock traded up $0.01 on Friday, reaching $0.87. 35,749 shares of the stock were exchanged, compared to its average volume of 90,824. Alimera Sciences has a 1-year low of $0.72 and a 1-year high of $1.21. The stock’s fifty day simple moving average is $0.90.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Recommended Story: Market Perform

Get a free copy of the Zacks research report on Alimera Sciences (ALIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.